ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Physicians Still Hopeful About Desmoteplase For The Treatment Of Acute Ischemic Stroke Despite Negative Results
Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that physicians are still hopeful about
Paion/Lundbeck's desmoteplase despite recent negative results. Although
desmoteplase demonstrated efficacy on a stringent composite measure of
overall outcome when delivered within nine hours of stroke onset in the
DIAS-1 trial, the drug failed to meet the same efficacy outcome in the
larger DIAS-2 Phase III clinical trial. Experts interviewed by Decision
Resources suggest that issues of clinical trial design, rather than the
action of the drug, may have led to the failure of desmoteplase in the
DIAS-2 trial. Despite these findings, surveyed neurologists indicate that
they would prescribe the drug to 10% of their diagnosed acute ischemic
stroke patients.
According to the new report entitled: Acute Ischemic Stroke: Despite
Negative Results, Physicians Still Hopeful about Desmoteplase, surveyed
neurologists continue to identify a six-hour treatment window as the area
of greatest dissatisfaction. The development of a reperfusion agent with a
wider time window would represent an important near-term solution by
increasing the number of acute ischemic stroke patients who receive
treatment.
"Between the two emerging therapies included in this study,
desmoteplase appears to have the potential to meet many of the safety and
delivery criteria of our 'Minimal Acceptable' target product profile," said
Sami Fam, Ph.D., analyst at Decision Resources. "Surveyed neurologists
would treat 10% of their patients with such an agent -- that is three times
more than those who are getting treated currently with rt-PA. The arrival
of such a reperfusion agent would signal a new dawn for the treatment of
acute ischemic stroke, which is miserably undertreated today."
About Acute Ischemic Stroke: Despite Negative Results, Physicians Still
Hopeful about Desmoteplase
Acute Ischemic Stroke: Despite Negative Results, Physicians Still
Hopeful about Desmoteplase is a DecisionBase 2008 report from Decision
Resources. DecisionBase 2008 combines market forecasts with clinical and
commercial end points to assess market share projections in 35 indications.
These outputs are driven by quantitative and qualitative primary research.
DecisionBase 2008 provides detailed market share, patient share, and
price-per-day projections for emerging drugs in development. The market
share projections are based on prescriber surveys that compare physicians'
expectations of a potential target product profile with an emerging product
profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members
of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a world leader
in market research publications, advisory services, and consulting designed
to help clients shape strategy, allocate resources, and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
Decision Resources
http://www.decisionresources.com
Medicii încã plin de speranþã despre Desmoteplase pentru tratamentul de accident vascular cerebral acut ischemicã în ciuda rezultatelor negative - Physicians Still Hopeful About Desmoteplase For The Treatment Of Acute Ischemic Stroke Despite Negative Results - articole medicale engleza - startsanatate